The American laboratory Lilly strengthens its roots in France


The new production line for the anti-diabetic Trulicity, now manufactured in Fegersheim. Lilly

This diabetes specialist announces 23.6 million euros of investment in Fegersheim (Alsace), its third largest site in the world. In total, he will have invested 550 million in ten years in this factory.

Lilly strengthens its roots in France. The American laboratory announced on Tuesday an investment of 23.6 million euros in Fegersheim (Alsace), its third largest site in the world. He had already indicated at the beginning of the year that he would inject 91 million euros into his Alsatian site which employs more than 1,200 people and 95% of whose production is exported. In total, Lilly will have invested 550 million euros in ten years in this factory. "Fegersheim is at the heart of our industrial strategy, says David Ricks, CEO of Lilly, which has five of its seven factories in Europe. After modernizing our production lines, we have chosen to manufacture some of the most promising new drugs in our portfolio on this site.»

Lilly will now manufacture in Fegersheim its anti-diabetic Trulicity (type 2 diabetes, the most widespread), the laboratory's blockbuster (6.5 billion dollars in turnover last year, +28%), which generates nearly a quarter of its annual sales...

This article is for subscribers only. You have 77% left to discover.

Cultivating your freedom is cultivating your curiosity.

Keep reading your article for €0.99 for the first month

Already subscribed?
Login



Source link